Physician profile
Gary T Anderson
NPI 1780687350
$694.59
in general payments reported to CMS, 2019-2025
23 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $137 · 2023: $113 · 2024: $149 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $120.83 | 2022-2025 | Breztri, Airsupra |
| Xeris Pharmaceuticals, INC. | $60.17 | 2024-2025 | Keveyis |
| Novo Nordisk INC | $55.34 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $45.87 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $45.77 | 2024-2025 | Zenpep |
| Kowa Pharmaceuticals America, INC. | $38.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.68 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.05 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $27.01 | 2021 | |
| Pfizer INC. | $26.28 | 2021-2024 | |
| Tempus Ai, INC | $23.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.80 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.81 | 2022 | |
| Eisai INC. | $19.63 | 2021 | |
| Horizon Therapeutics Plc | $16.97 | 2023 | Krystexxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.71 | 2023 | Otezla, Repatha |
| Collegium Pharmaceutical, INC. | $15.94 | 2025 | Belbuca |
| Teva Pharmaceuticals USA, INC. | $15.84 | 2022 | |
| Cepheid | $15.25 | 2025 | Genexpert |
| Gilead Sciences, INC. | $13.47 | 2024 | |
| Amarin Pharma, INC. | $13.13 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.75 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.